INSIGHTS ON CLINICAL TRIAL PARTNERING
-
![etmf-sites-GettyImages-1030071552]( "Five Questions Every Sponsor Must Ask Before Selecting An eTMF Platform")
Five Questions Every Sponsor Must Ask Before Selecting An eTMF PlatformLean teams need a strategic eTMF choice. The right platform speeds startup, cuts manual oversight, strengthens site collaboration, and keeps studies inspection‑ready as portfolios grow.
-
![IQVIA IRT SAVE]( "Benefit From Enhanced Power And Intelligence")
Benefit From Enhanced Power And IntelligenceFind a supply automation value engine with intelligent automation and algorithms to analyze drug supply data and automatically adjust delivery quantities to each site based on data available in IRT.
-
![Medical information chart-GettyImages-2228606051]( "Cagey Sponsors, Defensive Vendors: Observations On How Transparency Breaks Down")
Cagey Sponsors, Defensive Vendors: Observations On How Transparency Breaks DownDiscover how hidden operational uncertainties trigger defensive pricing and scope disputes—and how early transparency builds stable, high-performing research partnerships.
-
![Diverse multigenerational family walking in a park]( "ASGCT Symposium: Community-Based Cell & Gene Therapy Delivery")
ASGCT Symposium: Community-Based Cell & Gene Therapy DeliveryThis symposium from ASGCT 2026 explores community-based delivery of cell & gene therapies as a means to improve access, equity, enrollment speed, data quality, and regulatory evidence.
-
Do CROs Need To Reinvent Themselves In 2025?3/21/2025
Facing economic pressures, regulatory changes, and technological advancements, CROs must redefine their value propositions and discuss the need for reinvention in 2025 to accelerate into the future.
-
How To Optimize CMC And Clinical Strategies For Injectable, Oral Peptide Drugs3/17/2025
Advances in peptide drug delivery have opened new opportunities for peptide drug products, with non-parenteral routes of administration — such as oral and nasal — now feasible.
-
Central Laboratory Solutions9/29/2026
Global clinical trials need central laboratory networks able to scale across countries while keeping biomarker and biospecimen data consistent from one study site to the next.
-
Urgent Compliance Recovery Following Vendor Transition5/26/2026
Strong local leadership, clear ownership, and governed oversight drove rapid remediation of legacy safety gaps, restoring regulatory confidence and safeguarding market continuity.
-
Breaking Down Early Small Molecule Development3/11/2026
Adopt an integrated development strategy to streamline the path from early development to the clinic, ensuring timely clinical supply while reducing delays, risk, and inefficiencies.
CLINICAL TRIAL PARTNERING SOLUTIONS
-
![GettyImages-1332585814 oncology patient nurse]( "Your Partners In Drug Development And Safety")
How can Ergomed use its oncology expertise, global reach, and access to patients with rare and ultra-rare diseases can help your organization achieve efficient, high-quality clinical trial execution?
-
![Altasciences_Award-Winning Clinical Research Services For Early-Phase Drug Development]( "Award-Winning Clinical Research Services For Early-Phase Drug Development")
Explore the breadth of Altasciences’ expertise in clinical pharmacology studies, supporting regulatory submissions across a diverse range of therapeutic areas.
-
![GettyImages-1059548518 global conntection]( "Getting Biotechs GlobalReady")
Our proprietary GlobalReady model covers the entire drug development journey from robust EARLY PHASE clinical foundations with ClinicReady to seamless multi-regional Late phase expansion. All managed by the one award-winning CRO, saving time and costs and delivering rigorous globally accepted data.
-
![Speaking meeting]( "Biometrics")
Advancing a novel therapy through clinical development is complicated. Not all therapies make it to the patients that need them.
-
![Medicine-pills-tablets-GettyImages-545993684]( "Human Abuse Potential")
With over 60 HAP studies successfully conducted in the last decade, Altasciences has experience in diverse areas such as for stimulants, opioids, and sedative-hypnotics.
